Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
A., Monnier, M., Waser, P
In a double-blind phase 2 trial, 157 recruited vitiligo patients were randomized, in a 1:1:1:1:1 ratio, to receive topical ruxolitinib cream 1.5% BID, 1.5% QD, 0.5% QD, 0.15% QD, or a vehicle for 24 weeks, with the result showing considerably decreased CXCL9 and CXCL10 expression in 1.5% BID and 1.5% QD groups, and more individuals in groups receiving ruxolitinib cream 1.5% BID, 1.5% QD and 0.5% QD achieving F-VASI50, during which 1.5% BID group produced the highest responses in F-VASI50 (58%), F-VASI75 (52%), and F-VASI90 (33%)
*Correspondence: Helena D
A hypoallergenic body wash helps remove skin impurities thoroughly with deep hydration
Business Type Exporter, Manufacturer, Supplier Employee Count 10 Establishment 2018 Working Days To GST NO 27AASFG6496L1ZD Payment Mode Others Related Products Explore Related Categories More Products From This Seller Seller Details GST - 27AASFG6496L1ZD Nagpur, Maharashtra Accepts only Foreign inquiries Partner Mr Vinit Kalyani Address 102, Vidarbha Plaza, New Colony, Nagpur, Maharashtra, 440013, India Report incorrect details
US$ 24.47
US$ 28.89
US$ 26.20
US$ 20.59
US$ 28.51
